FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169876616> ?p ?o ?g. }

• W3169876616 endingPage "106677" @default.
• W3169876616 startingPage "106677" @default.
• W3169876616 abstract "Recent preclinical and clinical studies suggest that lorcaserin, a preferential serotonin 2C receptor (5-HT2CR) agonist that was approved for the treatment of obesity, possesses antiepileptic properties. Here, we tested whether lorcaserin (1, 3, 5.6, 10 mg/kg) is prophylactic against audiogenic seizures (AGSs) in juvenile Fmr1 knockout mice, a mouse model of fragile X syndrome (FXS). MPEP (30 mg/kg), a non-competitive mGluR5 receptor antagonist, was used as a positive control. As lorcaserin likely engages 5-HT2ARs at therapeutic doses, we pretreated one group of mice with the selective 5-HT2AR antagonist/inverse agonist, M100907 (0.03 mg/kg), alone or before administering lorcaserin (5.6 mg/kg), to discern putative contributions of 5-HT2ARs to AGSs. We also assessed lorcaserin's in vitro pharmacology at human (h) and mouse (m) 5-HT2CRs and 5-HT2ARs and its in vivo interactions at m5-HT2CRs and m5-HT2ARs. MPEP significantly decreased AGS prevalence (P = 0.011) and lethality (P = 0.038). Lorcaserin, 3 mg/kg, attenuated AGS prevalence and lethality by 14 % and 32 %, respectively, however, results were not statistically significant (P = 0.5 and P = 0.06); other doses and M100907 alone or with lorcaserin also did not significantly affect AGSs. Lorcaserin exhibited full efficacy agonist activity at h5-HT2CRs and m5-HT2CRs, and near full efficacy agonist activity at h5-HT2ARs and m5-HT2ARs; selectivity for activation of 5-HT2CRs over 5-HT2ARs was greater for human (38-fold) compared to mouse (13-fold) receptors. Lorcaserin displayed relatively low affinities at antagonist-labeled 5-HT2CRs and 5-HT2ARs, regardless of species. Lorcaserin (3 and 5.6 mg/kg) increased the 5-HT2AR-dependent head-twitch response (HTR) elicited by (±)-2,5-dimethoxy-4-iodoamphetamine (DOI) in mice (P = 0.03 and P = 0.02). At 3 mg/kg, lorcaserin alone did not elicit an HTR. If mice were treated with the selective 5-HT2CR antagonist SB 242084 (0.5 or 1 mg/kg) plus lorcaserin (3 mg/kg), a significantly increased HTR was observed, relative to vehicle (P = 0.01 and P = 0.03), however, the HTR was much lower than what was elicited by DOI or DOI plus lorcaserin. Lorcaserin, 3 mg/kg, significantly reduced locomotor activity on its own, an effect reversed by SB 242084, and lorcaserin also dose-dependently reduced locomotor activity when administered prior to DOI (Ps<0.002). These data suggest that lorcaserin may engage 5-HT2CRs as well as 5-HT2ARs in mice at doses as low as 3 mg/kg. The similar activity at m5-HT2CRs and m5-HT2ARs suggests careful dosing of lorcaserin is necessary to selectively engage 5-HT2CRs in vivo. In conclusion, lorcaserin was ineffective at preventing AGSs in Fmr1 knockout mice. Lorcaserin may not be a suitable pharmacotherapy for seizures in FXS." @default.
• W3169876616 created "2021-06-22" @default.
• W3169876616 creator A5014437784 @default.
• W3169876616 creator A5023735026 @default.
• W3169876616 creator A5074769127 @default.
• W3169876616 creator A5081049479 @default.
• W3169876616 creator A5091776135 @default.
• W3169876616 date "2021-09-01" @default.
• W3169876616 modified "2023-10-11" @default.
• W3169876616 title "Evaluation of lorcaserin as an anticonvulsant in juvenile Fmr1 knockout mice" @default.
• W3169876616 cites W146612229 @default.
• W3169876616 cites W1512233152 @default.
• W3169876616 cites W1537500038 @default.
• W3169876616 cites W1561479775 @default.
• W3169876616 cites W1897852281 @default.
• W3169876616 cites W1954851557 @default.
• W3169876616 cites W1965258805 @default.
• W3169876616 cites W1979175567 @default.
• W3169876616 cites W1981616104 @default.
• W3169876616 cites W1983746474 @default.
• W3169876616 cites W1990991409 @default.
• W3169876616 cites W1997231976 @default.
• W3169876616 cites W2009134620 @default.
• W3169876616 cites W2009570895 @default.
• W3169876616 cites W2015870346 @default.
• W3169876616 cites W2018838523 @default.
• W3169876616 cites W2021050939 @default.
• W3169876616 cites W2024952531 @default.
• W3169876616 cites W2028438346 @default.
• W3169876616 cites W2030308305 @default.
• W3169876616 cites W2038561863 @default.
• W3169876616 cites W2043949690 @default.
• W3169876616 cites W2058519592 @default.
• W3169876616 cites W2067481209 @default.
• W3169876616 cites W2068841959 @default.
• W3169876616 cites W2070335703 @default.
• W3169876616 cites W2084253035 @default.
• W3169876616 cites W2094993063 @default.
• W3169876616 cites W2095268995 @default.
• W3169876616 cites W2106499597 @default.
• W3169876616 cites W2125382272 @default.
• W3169876616 cites W2132972202 @default.
• W3169876616 cites W2134884548 @default.
• W3169876616 cites W2136176151 @default.
• W3169876616 cites W2141655487 @default.
• W3169876616 cites W2150904334 @default.
• W3169876616 cites W2156407398 @default.
• W3169876616 cites W2161047862 @default.
• W3169876616 cites W2172145012 @default.
• W3169876616 cites W2273883605 @default.
• W3169876616 cites W2280631766 @default.
• W3169876616 cites W2341776053 @default.
• W3169876616 cites W2342387220 @default.
• W3169876616 cites W2461174743 @default.
• W3169876616 cites W2508917693 @default.
• W3169876616 cites W2526987586 @default.
• W3169876616 cites W2547918114 @default.
• W3169876616 cites W2564752384 @default.
• W3169876616 cites W2568121822 @default.
• W3169876616 cites W2576763726 @default.
• W3169876616 cites W2582692487 @default.
• W3169876616 cites W2592469547 @default.
• W3169876616 cites W2601085743 @default.
• W3169876616 cites W2620588197 @default.
• W3169876616 cites W2621905925 @default.
• W3169876616 cites W2759433538 @default.
• W3169876616 cites W2768189107 @default.
• W3169876616 cites W2888031074 @default.
• W3169876616 cites W2891354340 @default.
• W3169876616 cites W2893127180 @default.
• W3169876616 cites W2897623379 @default.
• W3169876616 cites W2902080627 @default.
• W3169876616 cites W2921991316 @default.
• W3169876616 cites W2922555277 @default.
• W3169876616 cites W2945087933 @default.
• W3169876616 cites W2947512707 @default.
• W3169876616 cites W2965632152 @default.
• W3169876616 cites W2970796236 @default.
• W3169876616 cites W2980349585 @default.
• W3169876616 cites W2981122688 @default.
• W3169876616 cites W2982612889 @default.
• W3169876616 cites W2999364864 @default.
• W3169876616 cites W2999684597 @default.
• W3169876616 cites W3007078750 @default.
• W3169876616 cites W3008738360 @default.
• W3169876616 cites W3013140475 @default.
• W3169876616 cites W3015140823 @default.
• W3169876616 cites W3024949323 @default.
• W3169876616 cites W3091369370 @default.
• W3169876616 cites W3096208965 @default.
• W3169876616 cites W3112535936 @default.
• W3169876616 cites W3116452987 @default.
• W3169876616 cites W4232072708 @default.
• W3169876616 doi "https://doi.org/10.1016/j.eplepsyres.2021.106677" @default.
• W3169876616 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8296307" @default.
• W3169876616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34130255" @default.
• W3169876616 hasPublicationYear "2021" @default.
• W3169876616 type Work @default.

• next